Skip to main content
. Author manuscript; available in PMC: 2016 May 10.
Published in final edited form as: Cancer Gene Ther. 2013 Jul 5;20(8):437–444. doi: 10.1038/cgt.2013.38

Figure 2.

Figure 2

Inhibition of endothelial cell migration. HMVEC-d were incubated with CM derived from U251 glioma cells treated with HSVQ or RAMBO. Additionally, they were treated with the indicated concentration of cilengitide. A: Representative images from the scratch wound assay. HMVEC-d were assayed for movement after 12 h of exposure to CM with HSVQ or RAMBO plus cilengitide. B: Higher concentrations of cilengitide decreased the rate of wound closure. Especially, wound closure was significantly decreased in cells treated with CM from RAMBO-treated cells compared with CM from HSVQ-treated cells (*: P = 0.010, **: P = 0.0019, and ***: P = 0.00020, respectively).